Revenue for Q1 FY23 has increased by 6% YoY to ₹ 52,154 millions. Profits have grown by 108% YoY to ₹ 11,876
Dr Reddy's Laboratories Ltd
-(DRREDDY)
XNSE:DRREDDY, XBOM:DRREDDY
Dr. Reddy’s Laboratories (DRREDDY) Q1 FY23 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE:DRREDDY) Q1 FY23 Earnings Concall dated Jul. 28, 2022 Corporate Participants: Amit Agarwal -- Head of Investor Relations and
Dr. Reddy’s Laboratories (DRREDDY) Q4 FY22 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE: DRREDDY) Q4 FY22 Earnings Concall dated May 19, 2022 Corporate Participants: Amit Agarwal -- Head of Investor Relations G V
Dr. Reddy’s Laboratories Q3 FY 2022 Research Tear Sheet
Dr. Reddy's Laboratories are an Indian multinational pharmaceutical company. The company is headquartered in Hyderabad, Telangana, India and Princeton, New Jersey, U.S. It was incorporated in
Dr. Reddy’s Laboratories (DRREDDY) Q3 FY22 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE:DRREDDY) Q3 FY22 Earnings Concall dated Jan. 28, 2022 Corporate Participants: Amit Agarwal -- Head of Investor Relations Parag
Infographic: All you need to know about Dr Reddy’s Labs Q2 performance
Dr. Reddy's Laboratories(NSE:DRREDDY) recently reported its second-quarter 2022 earnings results. The company had a consolidated revenue of ₹5,992 crores with a growth
Key highlights from Dr Reddy’s Q2 2022 earnings results
Dr Reddy’s Laboratories (NSE: DRREDDY) reported its second-quarter financial results for the period ended September 30, 2021. The company had total revenue
Dr.Reddy’s Laboratories Ltd (DRREDDY) Q3 FY21 Earnings Concall Transcript
Dr.Reddy's Laboratories Ltd (NSE: DRREDDY) Q3 FY21 earnings Concall dated Jan. 29, 2021. Corporate Participants: Amit Agarwal -- Head of Investor Relations